There are no major changes in overall asthma management in terms of drug treatment. However the updated guidance does address the recent licence extension for tiotropium, and notes that there appears to be benefit in adding it to inhaled corticosteroids and salmeterol in patients who remain symptomatic despite these medications (although there are very few clinical trials in this specific patient group to guide management).